Asadzadeh Zahra, Mohammadi Hamed, Safarzadeh Elham, Hemmatzadeh Maryam, Mahdian-Shakib Ahmad, Jadidi-Niaragh Farhad, Azizi Gholamreza, Baradaran Behzad
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Cell Immunol. 2017 Dec;322:15-25. doi: 10.1016/j.cellimm.2017.10.015. Epub 2017 Oct 31.
Immune system acts as a host defensive mechanism protecting against attacking pathogens and transformed cells, including cancer cells. Th17 cells are a specific subset of T helper lymphocytes determined by high secretion of IL-17 and other inflammatory cytokines. Th17 cells increase tumor progression by activating angiogenesis and immunosuppressive activities. They can also mediate antitumor immune responses through recruiting immune cells into tumors, stimulating effector CD8+ T cells, or surprisingly by altering toward Th1 phenotype and producing IFN-γ, so Th17 cells are supposed as a double-edged sword in cancer. A comprehensive approach to indicating the activity of Th17 cells in tumor progression could help in the planning of new therapeutic approaches specially targeting Th17 cells in cancer.
免疫系统作为一种宿主防御机制，可抵御入侵的病原体和转化细胞，包括癌细胞。Th17细胞是T辅助淋巴细胞的一个特定亚群，其特征是高分泌白细胞介素-17（IL-17）和其他炎性细胞因子。Th17细胞通过激活血管生成和免疫抑制活性促进肿瘤进展。它们还可通过将免疫细胞募集到肿瘤中、刺激效应性CD8+ T细胞，或者令人惊讶地向Th1表型转变并产生干扰素-γ（IFN-γ）来介导抗肿瘤免疫反应，因此Th17细胞在癌症中被认为是一把双刃剑。一种全面的方法来指示Th17细胞在肿瘤进展中的活性，可能有助于规划专门针对癌症中Th17细胞的新治疗方法。
